Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | SMG1 | Q96Q15 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 8/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17387770 | 1.00 | TBK1 (0.50) | TBK1ZAP70SMG1JAK2IKBKE | |
| SCHEMBL17387795 | 0.91 | SMG1 (0.54) | TBK1ZAP70SMG1JAK2IKBKE | |
| SCHEMBL17387799 | 0.91 | SMG1 (0.54) | TBK1ZAP70SMG1JAK2IKBKE | |
| SCHEMBL17387758 | 0.91 | JAK2 (0.58) | TBK1JAK2IKBKEJAK1JAK3 | |
| SCHEMBL17387759 | 0.91 | JAK2 (0.58) | TBK1JAK2IKBKEJAK1JAK3 | |
| SCHEMBL17387850 | 0.86 | ZAP70 (0.54) | TBK1ZAP70JAK2IKBKEJAK1 | |
| SCHEMBL15972105 | 0.86 | ZAP70 (0.54) | TBK1ZAP70JAK2IKBKEJAK1 | |
| SCHEMBL15972031 | 0.83 | JAK2 (0.43) | TBK1JAK2IKBKEJAK1JAK3 | |
| SCHEMBL17387857 | 0.83 | JAK2 (0.43) | TBK1JAK2IKBKEJAK1JAK3 | |
| SCHEMBL17387919 | 0.83 | SMG1 (0.55) | TBK1ZAP70SMG1JAK2IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | claimed |
| EP-2958910-B1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LTD (GB) | 2016-08-03 | — | — | EP | claimed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | claimed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2958910-B1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | TBK1, TBKBP1, TYMS | TBK1 1/4885ZAP70 445/4885SMG1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.